JP6063615B2 - 眼の医学的症状の治療用組成物 - Google Patents
眼の医学的症状の治療用組成物 Download PDFInfo
- Publication number
- JP6063615B2 JP6063615B2 JP2008270231A JP2008270231A JP6063615B2 JP 6063615 B2 JP6063615 B2 JP 6063615B2 JP 2008270231 A JP2008270231 A JP 2008270231A JP 2008270231 A JP2008270231 A JP 2008270231A JP 6063615 B2 JP6063615 B2 JP 6063615B2
- Authority
- JP
- Japan
- Prior art keywords
- inferior
- dominant
- retinitis pigmentosa
- congenital
- dystrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims description 31
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 28
- 208000002780 macular degeneration Diseases 0.000 claims description 24
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 208000035719 Maculopathy Diseases 0.000 claims description 17
- 206010010356 Congenital anomaly Diseases 0.000 claims description 12
- 208000001140 Night Blindness Diseases 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 9
- 208000036443 AIPL1-related retinopathy Diseases 0.000 claims description 7
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims description 7
- 201000007737 Retinal degeneration Diseases 0.000 claims description 7
- 201000008615 cone dystrophy Diseases 0.000 claims description 7
- 201000006754 cone-rod dystrophy Diseases 0.000 claims description 7
- 230000004258 retinal degeneration Effects 0.000 claims description 7
- 206010010559 Congenital night blindness Diseases 0.000 claims description 6
- 201000007500 hereditary night blindness Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000005587 Refsum Disease Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 208000030597 adult Refsum disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- OENHQHLEOONYIE-BVZAMQQESA-N 9-cis-beta-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-BVZAMQQESA-N 0.000 claims description 3
- 208000033810 Choroidal dystrophy Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 108010078286 Ataxins Proteins 0.000 claims description 2
- 102000014461 Ataxins Human genes 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 206010011891 Deafness neurosensory Diseases 0.000 claims description 2
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 claims description 2
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 claims description 2
- 101000825534 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S2 Proteins 0.000 claims description 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
- 208000014769 Usher Syndromes Diseases 0.000 claims description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
- 208000003571 choroideremia Diseases 0.000 claims description 2
- 208000030194 mouth disease Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims description 2
- 208000006992 Color Vision Defects Diseases 0.000 claims 3
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 208000007698 Gyrate Atrophy Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 201000007254 color blindness Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 201000000763 red color blindness Diseases 0.000 claims 1
- 201000000757 red-green color blindness Diseases 0.000 claims 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000004044 response Effects 0.000 description 21
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 9
- 230000004300 dark adaptation Effects 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 241000195633 Dunaliella salina Species 0.000 description 5
- 208000017442 Retinal disease Diseases 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 3
- 230000004301 light adaptation Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-MKOSUFFBSA-N 9-cis-retinal Chemical compound O=C/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-MKOSUFFBSA-N 0.000 description 2
- 201000009487 Amblyopia Diseases 0.000 description 2
- 101150069031 CSN2 gene Proteins 0.000 description 2
- 206010007747 Cataract congenital Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 108700000201 Hyaloideoretinal degeneration of Wagner Proteins 0.000 description 2
- 208000032578 Inherited retinal disease Diseases 0.000 description 2
- 208000009795 Microphthalmos Diseases 0.000 description 2
- 208000016113 North Carolina macular dystrophy Diseases 0.000 description 2
- 208000032430 Retinal dystrophy Diseases 0.000 description 2
- 208000027073 Stargardt disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000006321 fundus dystrophy Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 201000010478 microphthalmia Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000036320 CAPN5-related vitreoretinopathy Diseases 0.000 description 1
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 description 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 description 1
- 241000195634 Dunaliella Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
- 208000037312 Familial drusen Diseases 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 201000008645 Joubert syndrome Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000000743 Marshall syndrome Diseases 0.000 description 1
- 108700000227 Marshall syndrome Proteins 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000034247 Pattern dystrophy Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 201000006760 Senior-Loken syndrome Diseases 0.000 description 1
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
- 208000027077 Stickler syndrome Diseases 0.000 description 1
- 206010044041 Tooth hypoplasia Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000022482 Wagner disease Diseases 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 1
- -1 all-trans-retinal aldehydes Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000006623 congenital stationary night blindness Diseases 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 201000002268 dental enamel hypoplasia Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000002570 electrooculography Methods 0.000 description 1
- 230000005221 enamel hypoplasia Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000008808 progressive bifocal chorioretinal atrophy Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000029941 retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations Diseases 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 210000004358 rod cell outer segment Anatomy 0.000 description 1
- ZFMRLFXUPVQYAU-UHFFFAOYSA-N sodium 5-[[4-[4-[(7-amino-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)O)N=NC5=CC(=C(C=C5)O)C(=O)O.[Na+] ZFMRLFXUPVQYAU-UHFFFAOYSA-N 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
被検者
正常人:年齢58.6±5.6才の眼科検診において何の病状もない5人の被検者に、約50%のオール-trans-β-カロチンと50%の9-cis-β-カロチン異性体とを含む市販のDunaliella Bardawil (DUNA)を毎日4カプセル(15mg)90日間与えた。被検者の視力、マイクロスコピカル眼圧及び網膜電位図(ERG)について試験前及び90日間の治療後に試験を行った。正常人及び(弱視を除く)患者の両目に対して治療の前後に視野中心24-2閾値テストを行った。
治療の前において、視力が20/200の弱視である1人の患者を除いて、全ての正常人及び患者の両目の最良修正視力は20/20であった。
結果は図1に要約されている。
正常人:正常人のERGの応答変化パーセンテージは表1にまとめられている。平均分離桿体(rod)応答振幅は、治療前において199±57μVであり、治療後には184±49μV(p=0.340、T-テスト)であった。最大暗順応のa波及びb波振幅応答は、基線と相違がなかった。治療前の平均a波振幅は186±61μVであり、治療後は181±28μVであった(p=0.307、T-テスト)。治療前の平均b波振幅は361±61μVであり、治療後は370±79μVであった(p=0.615、T-テスト)。明順応条件におけるERGの応答は基線から有意な差を示さなかった。治療前の平均a波振幅は28±4μVであり、治療後は25±5μVであった(p=0.451、T-テスト)。治療前の平均b波振幅は106±24μVであり、治療後は108±26μVであった(p=0.797、T-テスト)。30Hzフリッカー応答は、治療前の平均振幅が73±12μVであり、治療後の平均振幅が86±16μVであって基線から有意な差がなかった(p=0.099、T-テスト)。しかしながら、1人の被検者は両目における30Hz応答が90%という臨床的に有意な向上を示した。この向上は被検者数の少ないこのグループにおいては統計的に評価することはできなかった。
優勢網膜色素変性症
X連鎖型網膜色素変性症
不完全優勢X連鎖型網膜色素変性症
レーバー先天性黒内障
優勢レーバー先天性黒内障
網膜色素変性症による劣勢後柱運動失調
RPEの下肢小動脈蓄積による劣勢網膜色素変性症
網膜色素変性症RP12
アッシャー症候群
感音難聴を伴う優勢網膜色素変性症
劣勢白点状網膜症
劣勢アルストレーム症候群
劣勢バルデービードル症候群
黄班性ジストロフィー又は網膜変性を伴う優勢脊髄小脳性運動失調
劣勢無β-リポ蛋白血症
黄班変性を伴う劣勢網膜色素変性症
成人性劣勢レフサム病
小児性劣勢レフサム病
劣勢増進s錐体症候群
精神障害を伴う網膜色素変性症
筋障害を伴う網膜色素変性症
劣勢ニューファウンドランド桿体錐体ジストロフィー
網膜色素変性症sinpigmento
扇状網膜色素変性症
局所的網膜色素変性症
Senior-Loken症候群
ジュベール症候群
遅発性シュタルガルト病
優勢シュタルガルト型黄班性ジストロフィー
優勢シュタルガルト状黄班性ジストロフィー
劣勢黄班性ジストロフィー
劣勢黄色班眼底
劣勢錐体桿体ジストロフィー
X連鎖型進行性錐体桿体ジストロフィー
優勢錐体桿体ジストロフィー
錐体桿体ジストロフィー、グルーシー症候群
優勢錐体ジストロフィー
X連鎖型錐体ジストロフィー
劣勢錐体ジストロフィー
過剰桿体網膜電位を伴う劣勢錐体ジストロフィー
X連鎖型萎縮性黄班性ジストロフィー
X連鎖型網膜分離
優勢黄班性ジストロフィー
加齢性黄斑変性
優勢放射状黄班ドルーゼン
優勢標的黄班性ジストロフィー
優勢蝶型黄班性ジストロフィー
優勢成人卵黄様黄班性ジストロフィー
優勢ノースカロライナ黄班性ジストロフィー
優勢網膜錐体ジストロフィー1
優勢嚢形黄班性ジストロフィー
優勢異型卵黄様黄班性ジストロフィー
foveo黄班性萎縮症
優勢ベスト黄班性ジストロフィー
進行性優勢ノースカロライナ黄班性ジストロフィー
貧毛を伴う若年性劣勢黄班性ジストロフィー
劣勢中心窩発育不全及び前区発育異常
劣勢錐体順応遅延
青錐体単色症における黄班性ジストロフィー
2型糖尿病及び難聴を伴う黄班性パターンジストロフィー
神鳥班点網膜
パターンジストロフィー
優勢マーシャル症候群
優勢硝子体網膜変性症
優勢家族性滲出性硝子体網膜症
優勢硝子体網脈絡膜症候群
優勢新生血管炎症性硝子体網膜症
ゴールドマン-ファーヴル症候群
優勢第三色盲
劣勢桿体単色症
先天的赤緑色盲、緑色盲、赤色盲、緑色弱、赤色弱
Schubert-Bornschein型先天性停在夜盲症
劣勢小口病
優勢先天性停在夜盲症
劣勢先天性停在夜盲症
遅発性優勢黄班性ジストロフィー
劣勢白点眼底
X連鎖先天性停在夜盲症
不完全X連鎖先天性停在夜盲症
優勢限局性萎縮
優勢中心性輪紋状脈絡膜ジストロフィー
X連鎖コロイデレミア
乳頭状中心性輪紋脈絡膜萎縮
優勢進行性二重焦点脈絡網膜萎縮
進行性二重焦点脈絡網膜萎縮
エナメル質形成不全症
劣勢Bietti結晶性網膜角膜ジストロフィー
レーノー現象及び偏頭痛を伴う優勢遺伝性血管性網膜症
優勢ヴァーグナー病及びびらん性硝子体網膜症
劣勢小眼球症及び網膜症候群
劣勢小眼球症
劣勢遅滞、痙性、及び網膜変性
劣勢ボスニアジストロフィー
劣勢弾性線維仮黄色腫
劣勢バッテン病(若年型セロイド脂褐素症)
優勢アラジル症候群
マックシック−カフマン症候群
HARP症候群
劣勢ハレルフォルデン−シュバッツ症候群
優勢ソーズビー眼底ジストロフィー
オレゴン眼病
キーンズ・セイアー症候群
神経性異常を伴う発達性網膜色素変性症
Basseb Korenzweig症候群
フルラー病
サンフィリポ病
Scieie病
黒色腫を伴う網膜症
Sheen網膜ジストロフィー
デュシェーヌ黄班性ジストロフィー
ベッカー黄班性ジストロフィー
バードショット脈絡網膜炎
複数消失性白点症候群
急性帯状不顕性外網膜症
網膜静脈閉塞
網膜動脈閉塞
糖尿病性網膜症
網膜毒性
網膜傷害
網膜レーザー外傷
眼内異物金属
加齢性黄班変性
Claims (4)
- 9-cis-β-カロチンを含む藻類Dunallielaに由来する藻類粉末を含む、被検者の先天性夜盲症の眼の医学的症状の治療用又は予防用の経口医薬組成物であって、前記DunallielaがDunalliela Bardawilである、医薬組成物。
- 前記藻類粉末が新鮮又は乾燥したものである請求項1に記載の医薬組成物。
- 上記先天性夜盲症である、劣勢網膜色素変性症;優勢網膜色素変性症;X連鎖型網膜色素変性症;不完全優勢X連鎖型網膜色素変性症;レーバー先天性黒内障;優勢レーバー先天性黒内障;網膜色素変性症による劣勢後柱運動失調;RPEの下肢小動脈蓄積による劣勢網膜色素変性症;網膜色素変性症RP12;アッシャー症候群;感音難聴を伴う優勢網膜色素変性症;劣勢白点状網膜症;劣勢アルストレーム症候群;劣勢バルデービードル症候群;黄班性ジストロフィー又は網膜変性を伴う優勢脊髄小脳性運動失調;黄班変性を伴う劣勢網膜色素変性症;成人性劣勢レフサム病;小児性劣勢レフサム病;劣勢増進s錐体症候群;精神障害を伴う網膜色素変性症;筋障害を伴う網膜色素変性症;網膜色素変性症sinpigmento;扇状網膜色素変性症;局所的網膜色素変性症;劣勢錐体桿体ジストロフィー;X連鎖型進行性錐体桿体ジストロフィー;優勢錐体桿体ジストロフィー;錐体桿体ジストロフィー、グルーシー症候群;優勢錐体ジストロフィー;X連鎖型錐体ジストロフィー;劣勢錐体ジストロフィー;劣勢色盲;優勢第三色盲;劣勢桿体単色症;先天的赤緑色盲、緑色盲、赤色盲、緑色弱、赤色弱;Nougaret型優勢先天性停在夜盲症;Schubert-Bornschein型先天性停在夜盲症;劣勢小口病;優勢先天性停在夜盲症;劣勢先天性停在夜盲症;遅発性優勢黄班性ジストロフィー;劣勢白点眼底;X連鎖先天性停在夜盲症;不完全X連鎖先天性停在夜盲症;劣勢脳回転状萎縮;X連鎖コロイデレミア;神経性異常を伴う発達性網膜色素変性症の眼の医学的症状を治療又は予防するための請求項1又は2に記載の医薬組成物。
- 先天性停在夜盲症の眼の医学的症状を治療する又は予防するための請求項1又は2に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7144708P | 2008-04-29 | 2008-04-29 | |
US61/071,447 | 2008-04-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014023454A Division JP2014129367A (ja) | 2008-04-29 | 2014-02-10 | 眼の医学的症状の治療用組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009263328A JP2009263328A (ja) | 2009-11-12 |
JP2009263328A5 JP2009263328A5 (ja) | 2011-10-27 |
JP6063615B2 true JP6063615B2 (ja) | 2017-01-18 |
Family
ID=41389647
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008270231A Active JP6063615B2 (ja) | 2008-04-29 | 2008-10-20 | 眼の医学的症状の治療用組成物 |
JP2014023454A Pending JP2014129367A (ja) | 2008-04-29 | 2014-02-10 | 眼の医学的症状の治療用組成物 |
JP2016083202A Pending JP2016135800A (ja) | 2008-04-29 | 2016-03-31 | 眼の医学的症状の治療用組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014023454A Pending JP2014129367A (ja) | 2008-04-29 | 2014-02-10 | 眼の医学的症状の治療用組成物 |
JP2016083202A Pending JP2016135800A (ja) | 2008-04-29 | 2016-03-31 | 眼の医学的症状の治療用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (3) | JP6063615B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133552A2 (en) | 2008-04-29 | 2009-11-05 | Nikken Sohonsha Corporation | Methods of treating ophthalmic disorders |
JP6063615B2 (ja) * | 2008-04-29 | 2017-01-18 | 株式会社日健総本社 | 眼の医学的症状の治療用組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0487575T3 (da) * | 1989-08-17 | 1994-11-28 | Cortecs Ltd | Farmaceutiske formuleringer |
US20060281821A1 (en) * | 2003-03-14 | 2006-12-14 | Krzysztof Palczewski | Retinoid replacements and opsin agonists and methods for the use thereof |
JP2007153842A (ja) * | 2005-12-07 | 2007-06-21 | Hideki Aoki | ビタミンアパタイト複合体 |
CA2644423A1 (en) * | 2006-03-24 | 2007-10-04 | Ian Simon Tracton | Stable packaged dosage form and process therefor |
JP6063615B2 (ja) * | 2008-04-29 | 2017-01-18 | 株式会社日健総本社 | 眼の医学的症状の治療用組成物 |
-
2008
- 2008-10-20 JP JP2008270231A patent/JP6063615B2/ja active Active
-
2014
- 2014-02-10 JP JP2014023454A patent/JP2014129367A/ja active Pending
-
2016
- 2016-03-31 JP JP2016083202A patent/JP2016135800A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2009263328A (ja) | 2009-11-12 |
JP2016135800A (ja) | 2016-07-28 |
JP2014129367A (ja) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schatz et al. | Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study | |
Jacobson et al. | Relatively enhanced S cone function in the Goldmann-Favre syndrome | |
Heher et al. | The Natural History of Leber's Congenital Amoaurosis: Age-related Findings in 35 Patients | |
US8961993B2 (en) | Method of treating retinitis pigmentosa | |
Heckenlively | Preserved para-arteriole retinal pigment epithelium (PPRPE) in retinitis pigmentosa. | |
Hirose et al. | Retinal function in birdshot retinochoroidopathy | |
Cogan et al. | Ocular abnormalities in abetalipoproteinemia: a clinicopathologic correlation | |
JP6063615B2 (ja) | 眼の医学的症状の治療用組成物 | |
Hansen et al. | Refsum's Disease: Eye manifestations in a patient treated with low phytol low phytanic acid diet | |
JP2011518875A5 (ja) | ||
Cortin et al. | A patterned macular dystrophy with yellow plaques and atrophic changes. | |
Meyer et al. | Dominant retinitis pigmentosa: a clinicopathologic correlation | |
Han et al. | Electro-oculography in autosomal dominant vitreoretinochoroidopathy | |
Massof et al. | Vision threshold profiles in sector retinitis pigmentosa | |
Gundogan et al. | Electroretinogram in hereditary retinal disorders | |
Fishman et al. | Reticular tapeto-retinal dystrophy. As a possible late stage of Sjögren's reticular dystrophy. | |
Cunha-Vaz | Vitreous fluorophotometry recordings in posterior segment disease | |
Challiol et al. | Retinal toxicity due to canthaxanthin. Case series | |
Behrman et al. | Electrodiagnostic findings in quinine amblyopia. | |
Wu et al. | Hereditary hemorrhagic macular dystrophy | |
Yamamoto et al. | Mild retinal changes in a 47-year-old patient with phytanic acid storage disease | |
Mermeklieva | Role of Electrophysiological Methods in Diagnosis of Hereditary Retinal Dystrophies | |
Sharma et al. | Retinitis pigmentosa and allied disorders | |
GODEL et al. | Functional evaluation in Harada's disease | |
Korzhavina | NEW TRENDS IN THE DETECTION AND TREATMENT OF RETINITIS PIGMENTOSA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110909 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130814 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160708 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6063615 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |